Nexalin Technology Secures $5 Million to Transform Non-Invasive Mental Health Treatment

Nexalin Technology is excited to announce that it has successfully raised $5,000,000 in funding, marking a pivotal milestone for the company as it continues to deliver innovative, non-invasive, and drug-free therapy for those living with anxiety, depression, and insomnia. This significant capital infusion will empower Nexalin to accelerate research, expand clinical trials, and enhance the global reach of its groundbreaking therapy. At the heart of Nexalin’s approach is its patented waveform technology, protected under U.S. Patent #6904322B2, which forms the basis of its Transcranial Electrical Stimulation (TES) device. Clinical trials have demonstrated that this unique waveform not only raises beta-endorphin levels effectively but also promotes a natural, lasting balance in brain chemistry by normalizing various neurochemicals such as enkephalins, serotonin, and dopamine. With rigorous safety analyses backing its use and an FDA non-significant risk classification for clinical trials, the Nexalin device offers a promising alternative for individuals seeking treatment without the complications that can come from traditional drug therapies. The latest funding round will enable Nexalin Technology to further refine its patented electrical stimulation approach, deepen its understanding of the underlying neurophysiological mechanisms, and potentially pave the way for new applications in mental health therapeutics. As the company works to extend its clinical research and broaden its market presence, this investment underscores the growing confidence of the investment community in Nexalin’s vision—a future where technological innovation meets compassionate care to provide safer, more effective solutions for mental health challenges.